Abstract:Histamine H-3 receptor antagonists are being developed to treat a variety of neurological and cognitive disorders that may be ameliorated by enhancement of central neurotransmitter release. Here, we present the in vitro pharmacological and in vivo pharmacokinetic profiles for the nonimidazole, benzofuran ligand ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile] and compare it with several previously described imidazole and nonimidazole H-3 receptor antagonists. ABT-239 binds to recombinant human and rat H-3 receptors with high affinity, with pK(i) values of 9.4 and 8.9, respectively, and is over 1000-fold selective versus human H-1, H-2, and H-4 histamine receptors. ABT-239 is a potent H-3 receptor antagonist at recombinant human and rat receptors, reversing agonist-induced changes in cAMP formation (pK(b) = 7.9 and 7.6, respectively), guanosine 5'-O-(3-[S-35]thio) triphosphate ([S-35]GTP gamma S) binding (pK(b) = 9.0 and 8.3, respectively), and calcium mobilization (human pK(b) = 7.9). ABT-239 also competitively reversed histamine-mediated inhibition of [H-3]histamine release from rat brain cortical synaptosomes (pK(b) = 7.7) and agonist-induced inhibition of contractile responses in electric field stimulated guinea pig ileal segments (pA(2) = 8.7). Additionally, ABT-239 is a potent inverse agonist, inhibiting constitutive [S-35]GTP gamma S binding at both rat and human H-3 receptors with respective pEC(50) values of 8.9 and 8.2. ABT-239 demonstrates good pharmacokinetic characteristics in rat, dog, and monkey with t(1/2) values ranging from 4 to 29 h, corresponding with clearance values and metabolic turnover in liver microsomes from these species, and good oral bioavailability ranging from 52 to 89%. Thus, ABT-239 is a selective, nonimidazole H-3 receptor antagonist/inverse agonist with similar high potency in both human and rat and favorable drug-like properties.

Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.

Novel Heterocyclic-Substituted Benzofuran Histamine H-3 Receptor Antagonists: in Vitro Properties, Drug-Likeness, and Behavioral Activity

Design and synthesis of novel 3-substituted-indole derivatives as selective H3 receptor antagonists and potent free radical scavengers.

Non-Imidazole Histamine H3 Ligands. Part VII. Synthesis, In Vitro and In Vivo Characterization of 5-Substituted-2-thiazol-4-n-propylpiperazines

Design, Synthesis, and Biological Evaluation of Novel Iso-Flavones Derivatives As H3R Antagonists

( S )- N -Benzyl-1-phenyl-3,4-dihydroisoqunoline-2(1 H )-carboxamide Derivatives, Multi-Target Inhibitors of Monoamine Oxidase and Cholinesterase: Design, Synthesis, and Biological Activity.

Preliminary studies of 1,5-benzoxazepine derivatives as potential histamine H3 receptor antagonists

In Silico Analysis, Synthesis, and Biological Evaluation of Triazole Derivatives as H1 Receptor Antagonist

Synthesis and Biological Activity of Benzo[h]quinolinium Hydrazine Compounds

Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists

Structure-Activity Relationship of Hetarylpropylguanidines Aiming at the Development of Selective Histamine Receptor Ligands†

Isoquinolinone Derivatives As Potent CNS Multi-Receptor D2/5-HT1A/5HT2A/5-HT6/5-HT7 Agents: Synthesis and Pharmacological Evaluation

Isoquinolinone derivatives as potent CNS multi-receptor D2/5-HT1A/5-HT2A/5-HT6/5-HT7 agents: Synthesis and pharmacological evaluation

Synthesis, Biological Evaluation and SAR Studies of Benzimidazole Derivatives As H1-antihistamine Agents

Pharmacological Properties Of Abt-239 [4-(2-{2-[(2r)-2-Methylpyrrolidinyl]Ethyl}-Benzofuran-5-Yl)Benzonitrile] : I. Potent And Selective Histamine H-3 Receptor Antagonist With Drug-Like Properties

Design, Synthesis and Biological Activity Evaluation of Desloratadine Analogues As H1 Receptor Antagonists.

Synthesis and Biological Evaluation of a Novel Sigma-1 Receptor Antagonist Based on 3,4-Dihydro-2(1h)-quinolinone Scaffold As a Potential Analgesic.

Studies of Heterocyclic Compounds. VIII. Synthesis, Anti‐inflammatory and Antiallergic Activities of N‐alkyl‐2,3,4,9‐tetrahydrofuro[2,3‐b]quinoline‐3,4‐diones and Related Compounds

Design, Synthesis and Biological Activity of a Novel Ethylenediamine Derivatives As H1 Receptor Antagonists.

Synthesis and Antihistamine Evaluations of Novel Loratadine Analogues

[Synthesis and Anti-Histamine Release Activity of Phenyl Tetrazole Compounds].